Unlike regular chemotherapy, rituxan does not cause low blood counts or hair loss.
和常规化疗不同的是，美罗华不导致血细胞减少或脱发。
"We like Rituxan, and we think those trials are going to be successful," Flynn said.
福林说，我们喜欢Rituxan，我们认为试验将会成功。
Rituxan is currently approved as a treatment for non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.
Rituxan现在已经被批准用于非霍奇金淋巴瘤、慢性淋巴细胞白血病和风湿性关节炎的治疗。
Patients receiving Rituxan had a higher rate of infections at 37%, compared with 22% in the group of patients who didn't receive Rituxan as maintenance therapy.
但是服用Rituxan的病人受感染的几率为37%，高于没有服用Rituxan的病人的22%。
Retreatment with Rituxan was not formally evaluated; therefore, the safety and efficacy of retreatment with subsequent courses of Rituxan has not been established.
使用Rituxan的再治疗还未进行过正式评价，因此Rituxan后续进行再治疗的安全性和有效性还未能证实。
Objective To investigate the adverse reactions of rituximab (Rituxan and MabThera) in retrospection to provide references for safe and rational drug use clinically.
目的探讨抗肿瘤靶向药物利妥昔单抗（美罗华）不良反应的特点及规律，为临床安全、合理用药提供参考。
In March, Roche and Biogen Idec filed an application with the U.S. Food and Drug Administration seeking expanded approval of Rituxan as reflected in the study's findings.
三月份，罗氏和生物基因艾迪克就研究中的新发现向美国食品药品监督管理局(Foodand Drug Administration)提出新应用的申请。
In March, Roche and Biogen Idec filed an application with the U.S. Food and Drug Administration seeking expanded approval of Rituxan as reflected in the study's findings.
三月份，罗氏和生物基因艾迪克就研究中的新发现向美国食品药品监督管理局(Foodand Drug Administration)提出新应用的申请。
应用推荐